Back to results
US 2020/0347092 A1Published application
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
AssigneeEnanta Pharmaceuticals, Inc.
InventorsGuoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
Claims19
A compound represented by Formula V-A or Formula V-B, or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is selected from the group consisting of:
- 1) Halogen;
- 2) Hydroxyl;
- 3) Substituted or unsubstituted —C1-C8 alkyl;
- 4) Substituted or unsubstituted —C2-C8 alkenyl;
- 5) Substituted or unsubstituted —C2-C8 alkynyl;
- 6) Substituted or unsubstituted —C3-C8 cycloalkyl;
- 7) Substituted or unsubstituted aryl;
- 8) Substituted or unsubstituted arylalkyl;
- 9) Substituted or unsubstituted heterocycloalkyl;
- 10) Substituted or unsubstituted heteroaryl;
- 11) Substituted or unsubstituted heteroarylalkyl;
- and
- 12) —NR10R11;
- and
- m is selected from 0, 1, 2 and 3;
- R10 and R11 are each independently selected from hydrogen, substituted or unsubstituted —C1-C8 alkyl, substituted or unsubstituted —C2-C8 alkenyl, Substituted or unsubstituted —C2-C8 alkynyl, substituted or unsubstituted —C3-C8 cycloalkyl, or R10 and R11 are taken together with the nitrogen they attached form a heterocyclic ring.
15 more elements
2-9. (canceled)
(canceled)
Dependencies are inferred from the claim text.